Neurocrine Biosciences, Inc.
Eiry Roberts (Chief Medical Officer) reports NBIX insider transactions
About this filing
Neurocrine Biosciences, Inc. (NBIX) filed Form 4 (insider transaction) with the SEC on Nov 5, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Eiry Roberts · Chief Medical Officer
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | A · grantStock OptionFootnotes F1 | +8,314 | $0.00 | $0.00 | 8,314 | Direct |
| Nov 4, 2026 | A · grantRestricted Stock UnitFootnotes F2, F3 | +1,506 | $0.00 | $0.00 | 1,506 | Direct |
Footnotes
- F1 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 4, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F3 The Restricted Stock Units will settle annually at 1/4 of the units settling on each of November 4, 2027, November 4, 2028, November 4, 2029, and November 4, 2030.
More NBIX filings
- 4
Filed Nov 19, 2026
- 144
Filed Nov 17, 2026
- 144
Filed Nov 10, 2026
- 4
Filed Nov 3, 2026
- 4
Filed Nov 3, 2026
- 144
Filed Nov 2, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.